BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30784173)

  • 1. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.
    Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V
    J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
    Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
    Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
    Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
    J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
    Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
    Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
    Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
    J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
    Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells.
    Yamaga T; Suehiro J; Wada Y; Sakurai H
    Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
    Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
    Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
    Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
    Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells.
    Liu YH; Li YL; Shen HT; Chien PJ; Sheu GT; Wang BY; Chang WW
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
    Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK
    J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.
    Nishikubo K; Ohgaki R; Okanishi H; Okuda S; Xu M; Endou H; Kanai Y
    J Cell Mol Med; 2022 Oct; 26(20):5246-5256. PubMed ID: 36071551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
    Martinez RS; Salji MJ; Rushworth L; Ntala C; Rodriguez Blanco G; Hedley A; Clark W; Peixoto P; Hervouet E; Renaude E; Kung SHY; Galbraith LCA; Nixon C; Lilla S; MacKay GM; Fazli L; Gaughan L; Sumpton D; Gleave ME; Zanivan S; Blomme A; Leung HY
    Cancer Res; 2021 Jul; 81(13):3664-3678. PubMed ID: 33985973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
    Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
    Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
    Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
    Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
    Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
    J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells.
    Satou M; Wang J; Nakano-Tateno T; Teramachi M; Suzuki T; Hayashi K; Lamothe S; Hao Y; Kurata H; Sugimoto H; Chik C; Tateno T
    Mol Cell Endocrinol; 2020 Sep; 515():110868. PubMed ID: 32579901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
    Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
    J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.